Latham Advises on Aspen Neuroscience’s US$140.6 Million IPO

Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson’s disease, has announced the pricing of its initial public offering of 9,375,000 shares of common stock at a price to the public of US$15 per share. All of the shares of common stock are being offered by Aspen. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aspen, are expected to be approximately US$140.6 million. In addition, Aspen has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by New York partner Nathan Ajiashvili, San Diego partner Cheston Larson, and counsel Anthony Gostanian, with associates Omeed Valipour and Ariana Alemi.